Ensysce Biosciences Initiates Pivotal Phase 3 for PF614, Advances MPAR with FDA Breakthrough Therapy Support
Summary
Ensysce Biosciences reported its fourth quarter and full year 2025 financial results, though the primary focus of the announcement was on significant operational and clinical milestones. The company initiated a pivotal Phase 3 clinical trial for its lead drug candidate, PF614, an abuse-deterrent oxycodone. Additionally, Ensysce advanced its PF614-MPAR program, which combines abuse deterrence with overdose protection, receiving positive feedback from the FDA, including support for overdose-protection labeling and leveraging its Breakthrough Therapy designation. These clinical and regulatory advancements are material for a clinical-stage pharmaceutical company, indicating progress towards potential commercialization and strengthening its pipeline, which also includes a new candidate for opioid use disorder. This positive operational update provides a counter-narrative to the recent director resignation.
At the time of this announcement, ENSC was trading at $0.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9M. The 52-week trading range was $0.31 to $4.85. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Access Newswire.